ArticleCureus2026
Acute Appendicitis at Stem Cell Infusion During Autologous Transplantation for HIV-Associated Diffuse Large B-cell Lymphoma: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute appendicitis is an exceptionally rare complication of autologous hematopoietic stem cell transplantation (HSCT) and represents a diagnostic challenge, since its presentation overlaps with conditioning-related gastrointestinal toxicity and neutropenic enterocolitis. Published data are limited to isolated case reports, and its occurrence during autologous stem cell transplantation (ASCT) for human immunodeficiency virus (HIV)-associated lymphoma has not previously been described. We report the case of a 39-year-old man with HIV-associated diffuse large B-cell lymphoma (DLBCL), non-germinal center subtype, Ann Arbor stage IV with gastric involvement, and a high-risk age-adjusted International Prognostic Index (score three). After failure of first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with a Deauville score of four on interim positron emission tomography-computed tomography, complete metabolic remission was achieved with two cycles of second-line rituximab, dexamethasone, cytarabine, and carboplatin (R-DHAC). The patient then proceeded to carmustine, etoposide, cytarabine, and melphalan (BEAM)-conditioned ASCT under controlled HIV viral load and persistent CD4 lymphopenia. On the day of stem cell infusion (day zero), he developed right lower quadrant tenderness associated with elevated inflammatory markers; abdominopelvic computed tomography demonstrated acute appendicitis. Emergency laparoscopic appendectomy revealed ulcerative appendicitis without tumor infiltration on histopathology. The postoperative course during aplasia was complicated by septic shock due to multidrug-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.